Inner Banner

Principal Investigator

Dr. Rukmini Govekar

Dr. Rukmini Govekar

Principal Investigator

Research Interests

Delineating the molecular alterations mediating resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML)

RESEARCH

Chronic myeloid leukemia can be treated successfully by targeted therapy with tyrosine kinase inhibitors. However resistance to TKIs occurs in 10% of patients in chronic phase and 80% patients in the acute phase of blast crisis. In India patients report to clinic with advance disease. Moreover, age at onset is a decade earlier than in the western world, thus patient is on TKIs for longer period. Both of these increase the probability  of developing  resistance to TKIs. We aim to generate molecular profiles of CD34+ cells isolated from peripheral blood of  TKI-sensitive and –resistant chronic myeloid leukemia patients  in chronic as well as acute phase.  Multi-omics approach has been applied to understand and integrate alterations in different macromolecules. This would help to understand the molecular basis of resistance to tyrosine kinase inhibitors in CML.

Ongoing Research Projects

  • project1

    Reduced PKC Activity Induces Senescent Phenotype in Erythrocytes

    The molecular mechanism mediating expression of senescent cell antigen… more

  • project1

    Proteomic profiling of leukemic cells in Philadelphia chromosome positive leukemia

    Chronic myeloid leukemia (CML) epitomises successful targeted therapy with 90% pat… more

  • project1

    Genomic profiling of blast cells from different clinical stages of CML

    Chronic myeloid leukemia (CML) epitomises successful targeted therapy with 90% patients in chr… more

  • project1

    Genome-wide expression profiles of immature cells in the peripheral blood of patie…

    Despite the availability of imatinib mesylate, a targeted therapy for treatment of Chron… more

  • project1

    Alterations in the profile of metabolites from blast crisis chronic myeloid leukem…

    The discovery of tyrosine kinase inhibitors (TKIs) brought a major breakthrough in… more

Lab Members

PUBLICATIONS

Contact

Office Contact

Dr. Rukmini Govekar

KS 120B, Advance Centre for Treatment Research & Education in Cancer, Tata Memorial Centre, (ACTREC), Plot No. 1 & 2, Sector 22, Kharghar, Navi Mumbai-410210. Maharashtra India. +91 (022) 2740 5000/ 6873 5000 Extn-5023 rgovekar@actrec.gov.in
Back to Top